Skip to main content

Advertisement

Table 5 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and 5-FU in gastric cancer cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

YBC-2 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU     752.04 0.27 0.94
HER     1201.02 0.32 0.91
5-FU + HER 8060.81 1620.97 325.97 285.29 0.45 1
Diagnosis combined effect Antagonism Antagonism Antagonism    
YBC-3 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU     4.739 0.279 0.920
HER     46.063 0.623 0.970
5-FU + HER 75054 2.89E + 05 1.13E +06 71.077 0.207 0.928
Diagnosis combined effect antagonism antagonism antagonism    
NCI-N87 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU     119.61 0.25 0.97
HER     1.1E + 05 0.19 0.63
5-FU + HER 1.9E + 17 3.2E + 02 5.3E +29 3.7E + 14 −0.02 0.87
Diagnosis combined effect antagonism antagonism antagonism    
U-87 MG Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU     46.58 0.4 0.84
HER     1845.53 0.46 0.86
5-FU + HER 25540 4940.8 955.81 6.48 0.98 1
Diagnosis combined effect antagonism antagonism antagonism    
SK-BR-3 Combination Index value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
5-FU     753.42 0.52 0.93
HER     1.42E + 06 0.05 0.43
5-FU + HER 226.52 173.36 132.68 488.15 0.6 0.93
Diagnosis combined effect antagonism antagonism antagonism    
  1. DOX, Doxorubicin; HER, Herceptin; CI Combination index.